ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Non-Small-Cell Lung Carcinoma
Prostatic Cancer
Neoplasm Metastasis
Esophageal Cancer

Adenocarcinoma trials near Hanyang, Seoul, KOR:

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Enrolling
Resected Pancreatic Adenocarcinoma
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: daraxonrasib

Phase 3

Revolution Medicines
Revolution Medicines

Seoul, South Korea and 59 other locations

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 155 other locations

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Active, not recruiting
Gastroesophageal Cancer
Drug: Supportive care measures
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, South Korea and 168 other locations

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Drug: Sonesitatug vedotin
Drug: Nivolumab

Phase 3

AstraZeneca
AstraZeneca

Seoul, South Korea and 284 other locations

The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expre...

Enrolling
Pancreatic Ductal Adenocarcinoma (mPDAC)
GastroEsophageal Cancer
Drug: DA-3501

Phase 1

Dong-A ST

Seoul, Seoul, South Korea and 2 other locations

drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the firs...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
PDAC
Drug: Irinotecan
Drug: Telisotuzumab adizutecan

Phase 2, Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, South Korea and 20 other locations

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Seoul, South Korea and 118 other locations

Minnelide Once a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with Metastatic Adenocarcinoma...

Enrolling
Metastatic Adenocarcinoma of the Pancreas
Combination Product: Minnelide

Phase 1

Minneamrita Therapeutics

Soeul, Korea, Republic of

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: 5-Fluorouracil
Drug: XELOX

Phase 2

AstraZeneca
AstraZeneca

Seoul, South Korea and 43 other locations

Locations recently updated

esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Drug: Levoleucovorin
Drug: 5-Fluorouracil (5-FU)

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, South Korea and 51 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems